Capnia, Inc. (CAPN): Steinar J Engelsen , director of Capnia, Inc. purchased 58,200 shares on May 23, 2016. The Insider buying transaction was reported by the company on May 25, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.31 per share for a total value of $76,242.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 23, 2016, Steinar J Engelsen (director) purchased 18,821 shares at $1.23 per share price.On May 23, 2016, Ernest Mario (director) purchased 48,806 shares at $1.19 per share price.Also, On May 16, 2016, Bhatnagar Anish (CEO) purchased 5,000 shares at $1.15 per share price.On May 16, 2016, David D O’toole (officer ) purchased 5,000 shares at $1.15 per share price.
Shares of Capnia Inc (CAPN) ended Friday, May 20, 2016 session in red amid volatile trading. The shares closed down -0.02 points or -1.54% at $1.28 with 1,96,292 shares getting traded. Post opening the session at $1.29, the shares hit an intraday low of $1.2 and an intraday high of $1.34 and the price vacillated in this range throughout the day. The company has a market cap of $19,791 M and the number of outstanding shares has been calculated to be 15,46,20,00,000 shares. The 52-week high of Capnia Inc is $4.912 and the 52-week low is $0.843.
Capnia Inc. develops medical diagnostics and therapeutics based on its technology for precision metering of gas flow. The Company’s diagnostic product CoSense aids in the diagnosis of hemolysis in neonates. The Company is applying its research and development efforts to additional diagnostic products based on its Sensalyze Technology Platform a portfolio of methods and devices which enables CoSense and can be applied to detect a variety of analytes in exhaled breath. The Company’s therapeutic technology involves the use of metered nasal carbon dioxide (CO2) for the potential treatment of various diseases. Serenz is the Company’s allergy therapeutic product candidate. It also launched new initiatives for the development of this technology for the treatment of trigeminally mediated pain disorders such as cluster headache and trigeminal neuralgia.